Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynein axonemal heavy chain 8 (DNAH8) is a large motor protein component of the dynein motor complex, predominantly expressed in sperm and ciliary cells. It is critical for generating force that drives the movement of eukaryotic cilia and flagella via ATP hydrolysis and microtubule binding. DNAH8 contains conserved AAA+ ATPase domains, microtubule-binding regions, and is structurally related to other axonemal dyneins. Mutations or deficiencies in DNAH8 disrupt ciliary beating and sperm motility, resulting in diseases including primary ciliary dyskinesia, male infertility, and other ciliopathies. Recent evidence implicates DNAH8 as a regulator of androgen receptor activity, with high expression in prostate cancers associated with tumor metastasis, recurrence, and poor patient prognosis. DNAH8 is also essential for flagellar assembly and interacts with other dynein proteins such as DNAH17. There are currently no specific drugs targeting DNAH8, but experimental knockdown impacts cell proliferation in cancer models.
Experimental: siRNA-mediated knockdown reduces AR-dependent transcription and prostate cancer cell proliferation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynein axonemal heavy chain 8 (DNAH8).